These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12901953)

  • 1. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
    Ward SG; Finan P
    Curr Opin Pharmacol; 2003 Aug; 3(4):426-34. PubMed ID: 12901953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
    Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
    Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
    Ghigo A; Hirsch E
    Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
    Blunt MD; Ward SG
    Curr Opin Pharmacol; 2012 Aug; 12(4):444-51. PubMed ID: 22483603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective PI3Kδ inhibitors, a review of the patent literature.
    Norman P
    Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
    Foster JG; Blunt MD; Carter E; Ward SG
    Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
    Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ.
    Miller MS; Mountford SJ; Pinson JA; Zheng Z; Künzli M; Patel V; Hogg SJ; Shortt J; Jennings IG; Thompson PE
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4790-4794. PubMed ID: 27561716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K inhibitors as potential therapeutics for autoimmune disease.
    Ball J; Archer S; Ward S
    Drug Discov Today; 2014 Aug; 19(8):1195-9. PubMed ID: 24735732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K p110delta controls T-cell development, differentiation and regulation.
    Patton DT; Garçon F; Okkenhaug K
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):167-71. PubMed ID: 17371229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses.
    Hess KL; Donahue AC; Ng KL; Moore TI; Oak J; Fruman DA
    Eur J Immunol; 2004 Nov; 34(11):2968-76. PubMed ID: 15384044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the potential of PI3K inhibitors for inflammation and cancer.
    Crabbe T
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):253-6. PubMed ID: 17371252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity.
    Fruman DA
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):177-80. PubMed ID: 17371231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
    Ameriks MK; Venable JD
    Curr Top Med Chem; 2009; 9(8):738-53. PubMed ID: 19689378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K inhibitors in inflammation, autoimmunity and cancer.
    Stark AK; Sriskantharajah S; Hessel EM; Okkenhaug K
    Curr Opin Pharmacol; 2015 Aug; 23():82-91. PubMed ID: 26093105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2.
    Scozzafava A; Supuran CT
    Expert Opin Ther Pat; 2011 May; 21(5):803-6. PubMed ID: 21434841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
    Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
    J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease.
    Stokes CA; Condliffe AM
    Biochem Soc Trans; 2018 Apr; 46(2):361-369. PubMed ID: 29523773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node.
    Matheu MP; Deane JA; Parker I; Fruman DA; Cahalan MD
    J Immunol; 2007 Aug; 179(4):2261-9. PubMed ID: 17675487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.